4.8 Review

Roles for Innate Immunity in Combination Immunotherapies

期刊

CANCER RESEARCH
卷 77, 期 19, 页码 5215-5221

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-17-1340

关键词

-

类别

资金

  1. Koch Institute from the National Cancer Institute [P30-CA14051]
  2. Ragon Institute MGH, MIT, and Harvard
  3. Koch Institute for Integrative Cancer Research
  4. Dana Farber/Harvard Cancer Center (DF/HCC)
  5. Mayo Clinic-Koch Institute Collaboration
  6. Marble Center for Cancer Nanomedicine
  7. NIH [EB022433, CA172164, CA174795, CA206218]
  8. Stand Up To Cancer - Breast Cancer Research Foundation Convergence Team [SU2C-BCRF 2015-001]

向作者/读者索取更多资源

Immunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors. (C) 2017 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据